Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences (CRBU)
NASDAQ:CRBU
Caribou Biosciences (CRBU) Stock Price & Analysis
519 Followers
CRBU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.01 - $8.59
Previous Close$3.13
Volume3.67M
Average Volume (3M)1.80M
Market Cap
$282.69M
Enterprise Value-$19.02M
Total Cash (Recent Filing)$328.83M
Total Debt (Recent Filing)$27.11M
Price to Earnings (P/E)-2.2
Beta2.02
Next Earnings
Aug 06, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding90,317,771
10 Day Avg. Volume2,431,471
30 Day Avg. Volume1,803,855
Standard Deviation0.29
R-Squared0.23
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.83
Price to Sales (P/S)8.20
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.55
Enterprise Value/Gross Profit-0.55
Enterprise Value/Ebitda0.21
Forecast
1Y Price Target
$20.00Price Target Upside547.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Caribou Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCB-010 achieved a 94% objective response rate (ORR) and 69% complete response (CR) rate, presenting promising data for future study designs and potential treatments.
Financial StabilityCaribou ended 1Q24 with $345.9M in cash, cash equivalents, and marketable securities, providing a financial runway into 1Q26.
Product DevelopmentThe discovery of better responses from partial HLA matches in the ANTLER study may give Caribou more confidence to enter the autoimmune market.
Bears Say
Clinical TrialsConcerns about long-term efficacy and potential secondary malignancies with CAR Ts treatments are causing investor concerns.
Drug DevelopmentThe company's decision to pause development of a key preclinical therapy has brought about negative sentiment among investors.
Earnings RevisionAnalysts project a larger than previously estimated full-year net loss for the company.
---
Ownership Overview
8.74% Insiders
9.27% Mutual Funds
47.97% Other Institutional Investors
34.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $3.01 and its highest was $8.59 in the past 12 months.
What is Caribou Biosciences’s market cap?
Currently, no data Available
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Aug 06, 2024 which is in 76 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on May 07, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.411 by -$0.049.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -$0.46.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 90,317,770 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.411. Following the earnings report the stock price went down -6.166%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Among the largest hedge funds holding Caribou Biosciences’s share is Maverick Capital ltd. It holds Caribou Biosciences’s shares valued at 3M.
---
Caribou Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (547.25% Upside)
$20.00 (547.25% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 897.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.88%
12-Months-Change
Fundamentals
Return on Equity
-37.09%
Trailing 12-Months
Asset Growth
17.08%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
---
CRBU Stock 12 Month Forecast
Average Price Target
$20.00
▲(547.25% Upside)
Technical Analysis
Editas Medicine
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Beam Therapeutics
―
Best Analysts Covering CRBU
1 Year
1 Year Success Rate
2/20 ratings generated profit
1 Year Average Return
-26.71%
reiterated a buy rating 15 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -26.71% per trade.
---